Center Laboratories Inc (晟德大藥廠) yesterday said that it plans to “unblind” the data from the phase II clinical trial of its diabetes drug candidate CS02 in the second half of this year, after completing the “last patient’s last visit” late last month.
“Last patient’s last visit” is considered a milestone and the final step toward completion of a clinical trial.
The firm would collect and unblind the data to see if the experimental drug is safe and effective, general manager Robert Hsu (許瑞寶) told the Taipei Times by telephone.
The double-blind and placebo-controlled phase II clinical test randomized 185 patients into four groups that received a single dose of placebo or CS02 in dosages of 150mg, 300mg or 450mg, and then evaluated them over a 12-week period, Hsu said.
“We wanted to see which dosage would be optimal. As CS02 is developed to restore impaired beta-cells in pancreatic islets that synthesize and secrete insulin, we do not think higher doses would necessarily have a better effect,” Hsu said.
All of the enrolled patients were type 2 diabetes patients for whom the first-line treatment metformin proved ineffective, he said.
Center Laboratories aims to market CS02 as a second-line treatment for people with type 2 diabetes, Hsu said.
The company would see whether the enrolled patients’ glycosylated hemoglobin level, which reflects the average blood glucose level over the past three months, decreased after taking CS02 and check their beta-cell activity to determine whether the drug works, Hsu said.
“We would focus on the two gauges for the time being, given that global regulators have not set official gauges for the assessment of type 2 diabetes patients,” he said.
If approved for marketing, CS02 would be taken daily in the initial stage, but patients could gradually reduce the dosage and eventually stop taking the drug as their beta-cells would be restored, Hsu said.
After unblinding the data, the firm would apply to hold meetings with regulators in Taiwan and the US to review the results, and discuss the protocols for a phase III trial if the results are good, he added.
Center Laboratories would look for partners in the US and China to help conduct phase III trials there to alleviate its financial burden, but plans to conduct the final tests in Taiwan by itself, Hsu said.
The firm’s revenue dropped 14.81 percent to NT$307 million (US$10.27 million) in the first three months of this year, as the sales of some antiviral drugs fell due to fewer people catching the flu during the period, Hsu said, adding that Taiwanese paid more attention to their health amid the COVID-19 pandemic.
Hon Hai Precision Industry Co (鴻海精密) yesterday said that its research institute has launched its first advanced artificial intelligence (AI) large language model (LLM) using traditional Chinese, with technology assistance from Nvidia Corp. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), said the LLM, FoxBrain, is expected to improve its data analysis capabilities for smart manufacturing, and electric vehicle and smart city development. An LLM is a type of AI trained on vast amounts of text data and uses deep learning techniques, particularly neural networks, to process and generate language. They are essential for building and improving AI-powered servers. Nvidia provided assistance
GREAT SUCCESS: Republican Senator Todd Young expressed surprise at Trump’s comments and said he expects the administration to keep the program running US lawmakers who helped secure billions of dollars in subsidies for domestic semiconductor manufacturing rejected US President Donald Trump’s call to revoke the 2022 CHIPS and Science Act, signaling that any repeal effort in the US Congress would fall short. US Senate Minority Leader Chuck Schumer, who negotiated the law, on Wednesday said that Trump’s demand would fail, while a top Republican proponent, US Senator Todd Young, expressed surprise at the president’s comments and said he expects the administration to keep the program running. The CHIPS Act is “essential for America leading the world in tech, leading the world in AI [artificial
DOMESTIC SUPPLY: The probe comes as Donald Trump has called for the repeal of the US$52.7 billion CHIPS and Science Act, which the US Congress passed in 2022 The Office of the US Trade Representative is to hold a hearing tomorrow into older Chinese-made “legacy” semiconductors that could heap more US tariffs on chips from China that power everyday goods from cars to washing machines to telecoms equipment. The probe, which began during former US president Joe Biden’s tenure in December last year, aims to protect US and other semiconductor producers from China’s massive state-driven buildup of domestic chip supply. A 50 percent US tariff on Chinese semiconductors began on Jan. 1. Legacy chips use older manufacturing processes introduced more than a decade ago and are often far simpler than
Gasoline and diesel prices this week are to decrease NT$0.5 and NT$1 per liter respectively as international crude prices continued to fall last week, CPC Corp, Taiwan (CPC, 台灣中油) and Formosa Petrochemical Corp (台塑石化) said yesterday. Effective today, gasoline prices at CPC and Formosa stations are to decrease to NT$29.2, NT$30.7 and NT$32.7 per liter for 92, 95 and 98-octane unleaded gasoline respectively, while premium diesel is to cost NT$27.9 per liter at CPC stations and NT$27.7 at Formosa pumps, the companies said in separate statements. Global crude oil prices dropped last week after the eight OPEC+ members said they would
RSS